

PRESS RELEASE
18 March 2016



Resolutions of the Extraordinary General Meeting of BioInvent

Lund, Sweden – 18 March 2016 – Today's extraordinary general meeting in BioInvent International AB (publ) (BINV) resolved to amend the articles of association and approved the Board of Directors' resolution to carry out a new share issue with pre-emptive right for the shareholders of the company.

For the purpose of enabling the rights issue that was subject to approval by the general meeting, the meeting first resolved in accordance to the Board's proposal on amendment of the limits for the share capital and number of shares in the articles of association. The limits of the share capital were amended from no less than SEK 5,000,000 and no more than SEK 20,000,000 into no less than SEK 15,000,000 and no more than SEK 60,000,000, and the limits of the number of shares were amended from no less than 60,000,000 and no more than 240,000,000 into no less than 150,000,000 and no more than 600,000,000.

The general meeting thereafter resolved to approve the resolution by the Board of Directors on 16 February 2016 to issue new shares with pre-emptive right for the existing shareholders. According to the terms each share in BioInvent held on the record date for participation in the rights issue on 22 March 2016 entitles to one (1) subscription right, and five (5) subscription rights entitle to subscription for three (3) new shares. The subscription price has been set to SEK 1.95 per share, which represents total rights issue proceeds of approx. MSEK 191 before transaction costs. The subscription period will run from 29 March until 12 April 2016, with a right for Board of Directors to extend the subscription period. By the new share issue, the company's share capital will be increased by not more than SEK 7,820,110.08 through the issuance of a maximum number of 97,751,376 new shares.

Additional information regarding the rights issue will be included in the prospectus expected to be published around 23 March 2016.

The minutes from the extraordinary general meeting will be available on the company's webpage, www.bioinvent.com.

– END –

To the editors:

About BioInvent

BioInvent International AB develops immune oncology drugs. With one of the world's largest antibody libraries, and a unique, proprietary discovery method, BioInvent can identify the optimal cellular targets and antibodies for the treatment of various tumor types. BioInvent has also considerable experience in and a facility for process development and production of antibodies for clinical studies. This makes it possible to develop proprietary drug projects, but also to supply leading international pharmaceutical companies with effective tools for their drug development. BioInvent currently has three proprietary projects in or close to clinical development and partnership agreements with seven global pharmaceutical and biotech companies. More information is available at www.bioinvent.com.

For further information, please contact:

Björn O. Nilsson
Chairman of the Board
+46 (0)70218 15 00

Michael Oredsson
President and CEO
+46 (0)46 286 85 67
+46 (0)70716 89 30
michael.oredsson@bioinvent.com

BioInvent International AB (publ)

Co. reg. No: 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46(0)46 286 85 50
info@bioinvent.com
www.bioinvent.com

Important information

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in BioInvent. Any invitation to the persons concerned to subscribe for shares in BioInvent will only be made through the prospectus that BioInvent estimates to publish on or about 23 March 2016.

This press release may not be published or distributed, directly or indirectly in or into the United States, Canada, Hong Kong, Japan, South Africa, Australia or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in such a manner that contravenes such restrictions or would require such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.

No subscription rights, BTAs (interim shares) or new shares has been or will be registered under the United States Securities Act of 1933 ("Securities Act") or securities legislation in any other state or other jurisdiction in the United States and may not be offered, subscribed, sold or transferred, directly or indirectly within the United States, other than pursuant to an exemption from the registration requirements of the Securities Act and in accordance with securities laws in relevant state or other jurisdiction in the United States.

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 1.00 p.m. CET, on 18 March 2016.